- Home
- USIO vs TPST Comparison
USIO vs TPST Comparison
Compare USIO & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | USIO | TPST |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.0M | 30.9M |
| IPO Year | 1999 | 2012 |
Fundamental Metrics
Financial Performance| Metric | USIO | TPST |
|---|---|---|
| Price | $1.10 | $1.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $4.00 | ★ $10.00 |
| AVG Volume (30 Days) | 56.7K | ★ 120.4K |
| Earning Date | 03-18-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $28,200,535.00 | $295,000.00 |
| Revenue This Year | $15.47 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.69 | N/A |
| 52 Week Low | $1.03 | $0.60 |
| 52 Week High | $2.02 | $12.22 |
Technical Indicators
Market Signals| Indicator | USIO | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 34.19 | 26.09 |
| Support Level | $1.03 | N/A |
| Resistance Level | $1.42 | $2.49 |
| Average True Range (ATR) | 0.07 | 0.15 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 31.18 | 10.34 |
Price Performance
Historical ComparisonAbout USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for Output Solutions operations.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.